MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 859209-74-8
MCE 国际站:Rabacfosadine
产品活性:Rabacfosadine (GS-9219) 是核苷类似物 PMEG 的新型前体,用作优先靶向淋巴细胞的细胞毒性剂。
研究领域:Cell Cycle/DNA Damage
作用靶点:Nucleoside Antimetabolite/Analog
In Vitro: In lymphocytes, Rabacfosadine (GS-9219) is converted to its active metabolite, 9-(2-phosphonylmethoxyethyl)guanine (PMEG) diphosphate, via enzymatic hydrolysis, deamination, and phosphorylation. GS-9219 has substantial antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines. The ability of Rabacfosadine to inhibit the proliferation of activated lymphocytes and of tumor cells of hematopoietic origin is investigated. Rabacfosadine inhibits the proliferation of mitogen-stimulated T and B lymphocytes with EC50 values of 135 and 42 nM, respectively, as determined by BrdUrd incorporation. To compare the activity of GS-9219 in dividing and nondividing cells, Rabacfosadine is evaluated in these populations using a metabolism-based sodium XTT assay instead of BrdUrd assays. Results from the XTT assay shows a 127-fold difference between the EC50 values of Rabacfosadine in quiescent (EC50=17.2 μM) and proliferating (EC50=135 nM) cells. These results indicate a substantial selectivity of Rabacfosadine toward actively replicating lymphoblasts.
In Vivo: Rabacfosadine (RAB) has substantial single-agent activity in dogs with lymphoma, and a different mechanism of action than Doxorubicin (DOX). Open-label, multicenter prospective clinical trial. Dogs receive alternating Rabacfosadine (1.0 mg/kg IV weeks 0, 6, 12) and Doxorubicin (30 mg/m2 IV weeks 3, 9, 15). Dogs that achieved complete response (CR) are followed by monthly evaluations. Complete clinicopathological evaluation and assessment of remission and adverse event (AEs) are performed every 21 days. Acute AEs, occurring within 21 days after administration of the first dose of each agent, are compared between Rabacfosadine and Doxorubicin in 46 dogs receiving at least 1 dose of each agent.
相关产品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | Anti-Lung Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Heterocyclic Compound Library | 2’-dG (iBu)-2’-phosphoramidite | Peldesine dihydrochloride | 3’-Beta-C-Methyl-N6-(m-trifluoromethylbenzyl)adenosine | IBU-DC Phosphoramidite | 8-Methylguanosine | 2'-Deoxy-8-methylamino-adenosine | N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine | 7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 5’-Deoxy-5’-N-methylaminothymidine | N-Acetyl-2′-deoxycytidine | 5-Carboxymethylaminomethyluridine | 3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose | 3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine | 6-Mercaptopurine-13C2,15N | 4′,5′-Didehydro-5′-deoxyadenosine | 2’,3’,5’-Tri-O-acetyl-5,N3-dimethyluridine | 2’-Deoxy-2’-fluoro-N1-methyluridine | 5'-Homocytidine | 2'-Deoxypseudoisocytidine | 3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine | 5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine | 3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine | 2’-Deoxy-2’-fluoro-4-thio-beta-D-arabinouridine | 2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine | Uridine triphosphate-13C9,15N2 sodium | 2'-O-Methylinosine | 3-Methylcytidine | Uridine-d | Capecitabine-d11 | 5-Pyrrolidinomethyluridine
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-13640
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。